Evidence map›Paper›PMID 26876472›Full record

ArticleNeuroImage2016

Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism.

Anne Lingford-Hughes, James Myers, Ben Watson, Alastair G Reid, Nicola Kalk, Adrian Feeney, Alexander Hammers, Daniela A Riaño-Barros, Colm J McGinnity, Lindsay G Taylor and 4 more

Open access · hybridAbstract read
In one paragraph

Article in NeuroImage, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Anne Lingford-HughesCentre for Neuropsychopharmacology, Imperial College London, Du Cane Rd., London W12 0NN, United Kingdom; Psychopharmacology Unit, University of Bristol, Whitson Street, Bristol BS1 3NY, United Kingdom; MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom; Hammersmith Imanet Ltd., Hammersmith Hospital, Du Cane Rd., London W12 0NN, United Kingdom. Electronic address: anne.lingford-hughes@ic.ac.uk.
James MyersCentre for Neuropsychopharmacology, Imperial College London, Du Cane Rd., London W12 0NN, United Kingdom; Psychopharmacology Unit, University of Bristol, Whitson Street, Bristol BS1 3NY, United Kingdom; MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom.
Ben WatsonPsychopharmacology Unit, University of Bristol, Whitson Street, Bristol BS1 3NY, United Kingdom; MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom; Hammersmith Imanet Ltd., Hammersmith Hospital, Du Cane Rd., London W12 0NN, United Kingdom.
Alastair G ReidPsychopharmacology Unit, University of Bristol, Whitson Street, Bristol BS1 3NY, United Kingdom; MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom; Hammersmith Imanet Ltd., Hammersmith Hospital, Du Cane Rd., London W12 0NN, United Kingdom.
Nicola KalkCentre for Neuropsychopharmacology, Imperial College London, Du Cane Rd., London W12 0NN, United Kingdom; Psychopharmacology Unit, University of Bristol, Whitson Street, Bristol BS1 3NY, United Kingdom; MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom.
Adrian FeeneyPsychopharmacology Unit, University of Bristol, Whitson Street, Bristol BS1 3NY, United Kingdom; MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom.
Alexander HammersMRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom.
Daniela A Riaño-BarrosMRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom.
Colm J McGinnityMRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom.
Lindsay G TaylorPsychopharmacology Unit, University of Bristol, Whitson Street, Bristol BS1 3NY, United Kingdom.
Lula RossoMRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom.
David J BrooksMRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom; Hammersmith Imanet Ltd., Hammersmith Hospital, Du Cane Rd., London W12 0NN, United Kingdom.
Federico TurkheimerMRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom.
David J NuttCentre for Neuropsychopharmacology, Imperial College London, Du Cane Rd., London W12 0NN, United Kingdom; Psychopharmacology Unit, University of Bristol, Whitson Street, Bristol BS1 3NY, United Kingdom; MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, United Kingdom.
Imperial College London · GBHammersmith Hospital · GBUniversity of Bristol · GB

Funding

Medical Research Council G1002226Medical Research Council G1100809Medical Research Council G1100810Medical Research Council G400575Medical Research Council MC_U120036861
6 · The paper itself

Abstract

The importance of the GABA-benzodiazepine receptor complex and its subtypes are increasingly recognised in addiction. Using the α1/α5 benzodiazepine receptor PET radioligand [(11)C]Ro15 4513, we previously showed reduced binding in the nucleus accumbens and hippocampus in abstinent alcohol dependence. We proposed that reduced [(11)C]Ro15 4513 binding in the nucleus accumbens was a marker of addiction whilst the reduction in hippocampus and positive relationship with memory was a consequence of chronic alcohol abuse. To examine this further we assessed [(11)C]Ro15 4513 binding in another addiction, opiate dependence, and used spectral analysis to estimate contributions of α1 and α5 subtypes to [(11)C]Ro15 4513 binding in opiate and previously acquired alcohol-dependent groups. Opiate substitute maintained opiate-dependent men (n=12) underwent an [(11)C]Ro15 4513 PET scan and compared with matched healthy controls (n=13). We found a significant reduction in [(11)C]Ro15 4513 binding in the nucleus accumbens in the opiate-dependent compared with the healthy control group. There was no relationship between [(11)C]Ro15 4513 binding in the hippocampus with memory. We found that reduced [(11)C]Ro15 4513 binding was associated with reduced α5 but not α1 subtypes in the opiate-dependent group. This was also seen in an alcohol-dependent group where an association between memory performance and [(11)C]Ro15 4513 binding was primarily driven by α5 and not α1 subtype. We suggest that reduced α5 levels in the nucleus accumbens are associated with addiction since we have now shown this in dependence to two pharmacologically different substances, alcohol and opiates.

Indexed as

AdultAffinity LabelsAlcoholismAzidesBenzodiazepinesBrainCarbon RadioisotopesHippocampusHumansMaleMemoryNucleus AccumbensOpioid-Related DisordersPositron-Emission TomographyReceptors, GABA-AAffinity LabelsAzidesBenzodiazepinesCarbon RadioisotopesReceptors, GABA-ARo 15-4513

Identifiers

PMID26876472
PMCPMC4862962
OpenAlexW2255270868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.